Anti-TRIM59 / Tripartite motif-containing protein 59

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. TRIM59 antibody recognizes Tripartite motif-containing protein 59, an E3 ubiquitin ligase that regulates diverse cellular processes including innate immunity, oncogenic signaling, and protein stability. TRIM59 belongs to the TRIM family characterized by a RING finger domain, one or two B-box domains, and a coiled-coil region responsible for self-association and substrate recognition. As a member of this family, TRIM59 modulates ubiquitination and degradation of target proteins, influencing signal transduction, apoptosis, and transcriptional regulation. The TRIM59 antibody is widely used to investigate tumorigenesis, immune signaling, and ubiquitin-proteasome pathway regulation.TRIM59 is encoded by the TRIM59 gene on human chromosome 3q25.33. The protein localizes mainly to the cytoplasm but can translocate to the nucleus under specific signaling conditions. It interacts with multiple oncogenic and tumor-suppressive pathways, including p53, STAT3, and Ras-mediated cascades. Overexpression of TRIM59 has been documented in various cancers such as gastric, lung, and breast carcinoma, where it promotes cell proliferation, invasion, and resistance to apoptosis.Studies using the TRIM59 antibody have revealed that TRIM59 acts as an oncogenic factor by promoting ubiquitin-dependent degradation of p53, thereby suppressing apoptosis and enhancing tumor growth. Additionally, TRIM59 participates in innate immune signaling by modulating the STING and NF-kB pathways, influencing cytokine production during viral infection. Western blot analysis typically shows a band at approximately 42-48 kDa. Immunofluorescence using this antibody reveals diffuse cytoplasmic staining, occasionally enriched in perinuclear compartments.TRIM59 functions as part of a larger regulatory network controlling inflammation and autophagy. It has been associated with epigenetic modulation through interactions with chromatin-remodeling factors, affecting transcriptional activation of oncogenes. In cancer models, TRIM59 depletion suppresses tumor cell migration and enhances p53-dependent growth inhibition. NSJ Bioreagents offers a validated TRIM59 antibody optimized for western blot, immunohistochemistry, and immunofluorescence. This reagent supports mechanistic studies linking ubiquitination, cell signaling, and oncogenesis.